Table 1

 Baseline demographic data, clinical characteristics, and cytokine concentrations

IPFNSIPDIPTotalControls
(n = 39)(n = 6)(n = 4)(n = 49)(n = 15)
*p<0.05, **p<0.01 compared with IPF group.
M/F36/31/5**3/140/95/10
Mean (SE) age (years)60.4 (1.7)48.7 (4.7)*49.2 (5.7)58.0 (1.6)34.1 (2.1)
Smoking status
    Current6 (15%)1 (17%)1 (25%)8 (16%)1 (7%)
    Ex25 (64%)2 (33%)3 (75%)30 (61%)2 (13%)
    Never8 (21%)3 (50%)011 (22%)12 (80%)
Lung biopsy8 (21%)5 (83%)2 (50%)15 (31%)
No treatment224026
Prednisolone alone7119
Prednisolone+azathioprine4026
Other combination6118
Mean (range) duration of symptoms (months)52.5 (1.5–192)26.3 (4–109)29.8 (3–90)45.9 (1.5–192)
Mean (SE) lung function (% predicted)
    FEV171.6 (3.1)65.7 (9.3)64.1 (3.8)69.8 (2.7)
    FVC67.6 (3.1)62.9 (9.7)60.8 (6.3)66.0 (2.8)
    TLC65.1 (2.7)73.1 (19.4)64.7 (6.7)64.6 (2.5)
    Tlco40.8 (2.2)42.0 (24.1)44.2 (7.8)41.1 (2.0)
Plasma IL-8 (pg/ml)194 (86–307)172 (36–296)101 (42–357)155 (77–303)31 (0.0–100)
Plasma VEGF (pg/ml)662 (449–918)739 (401–862)878 (652–2014)672 (452–915)648 (433–734)
Plasma ET-1 (pg/ml)1.21 (0.88–2.00)1.22 (0.80–1.66)1.18 (0.94–2.33)1.21 (0.91–1.88)0.84 (0.67–1.13)